IDO1-BIN1 signature predicts AML survival and may be refined by adding IDO1-interacting genes. (A) Correlation between IDO1 and BIN1 gene expression values in the HOVON cases (r = −0.41, P < .0001). (B) Kaplan-Meier estimates of OS in the HOVON cases according to the IDO1-BIN1 score (P < .01). Patients were split into 3 different groups according to score quartiles. (C) Kaplan-Meier estimates of OS according to IDO2 expression in the TCGA-AML dataset (IDO2 median expression value used as cutoff, P < .05). (D) Kaplan-Meier estimates of OS according to PLXNC1 expression in the TCGA-AML dataset (PLXNC1 median expression value used as cutoff, P < .05). (E) Correlation between IDO1 and IDO2 gene expression values in the HOVON cases (r = 0.27, P < .0001). (F) Correlation between IDO1 and PLXNC1 gene expression values in the HOVON cohort of patients (r = −0.25, P < .0001). (G) Kaplan-Meier estimates of OS according to IDO2 expression in the HOVON dataset (IDO2 median expression value used as cutoff, P < .05). (H) Kaplan-Meier estimates of OS according to PLXNC1 expression in the HOVON dataset (PLXNC1 median expression value used as cutoff, P < .001).